Old Web
English
Sign In
Acemap
>
authorDetail
>
Radmila Kanceva
Radmila Kanceva
Medicine
Biosimilar
Internal medicine
Pegfilgrastim
Gastroenterology
4
Papers
8
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta® in Healthy Subjects: a Randomized, Double-blind Trial
2020
Clinical Therapeutics
Jason D. Lickliter
Radmila Kanceva
Emmanuelle Vincent
Armin Schueler
Eleanor Harrison-Moench
Corinne Seng Yue
Michael Stahl
Martin Ullmann
Vishal Ghori
Paul Griffin
Show All
Source
Cite
Save
Citations (1)
Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double‐blind trial
2020
Pharmacology Research & Perspectives
Chris Wynne
Christian Schwabe
Emmanuelle Vincent
Armin Schueler
Janka Ryding
Martin Ullmann
Vishal Ghori
Radmila Kanceva
Michael Stahl
Show All
Source
Cite
Save
Citations (1)
Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trial.
2019
Journal of Clinical Oncology
Jason D. Lickliter
Paul Griffin
Emmanuelle Vincent
Armin Schüler
Eleanor Harrison-Moench
Michael Stahl
Samer El Bawab
Radmila Kanceva
Pere Gascón
Show All
Source
Cite
Save
Citations (1)
A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease
2017
American Journal of Nephrology
Matthew R. Weir
Pablo E. Pergola
Rajiv Agarwal
Jeffrey C. Fink
Nelson Kopyt
Ajay K. Singh
Jayant Kumar
Susanne Schmitt
Gregor Schaffar
Anita Rudy
Jim P. McKay
Radmila Kanceva
Show All
Source
Cite
Save
Citations (5)
1
map